SignalXSignalX

COLL COLLEGIUM PHARMACEUTICAL, INC

Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
COLLEGIUM PHARMACEUTICAL, INC Overview

COLLEGIUM PHARMACEUTICAL, INC (COLL) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New FDA opioid labeling requirements effective July 31, 2025 mandate safety changes including overdose info, increasing compliance costs and marketing challenges
  • • Most updated risk: $581.3M 2024 Term Loan and $241.5M 2029 Convertible Notes increase financial leverage and interest rate exposure via SOFR-linked variable rates
+3 more insights

Get deeper insights on COLLEGIUM PHARMACEUTICAL, INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.